Bernd Seibel
Directeur Financier/CFO chez Zytoprotec GmbH
Profil
Bernd Seibel is currently the Vice Chairman at Hummingbird Diagnostics GmbH and the Chief Financial Officer & Director at Zytoprotec GmbH.
Previously, he served as the Director-Supervisory Board at SpePharm Holding BV and as the General Partner at TVM Capital GmbH from 1993 to 2010.
Mr. Seibel obtained his undergraduate degree from Universität zu Köln.
Postes actifs de Bernd Seibel
| Sociétés | Poste | Début |
|---|---|---|
Zytoprotec GmbH
 Zytoprotec GmbH Pharmaceuticals: MajorHealth Technology Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria. | Directeur Financier/CFO | - |
Hummingbird Diagnostics GmbH
 Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Bernd Seibel
| Sociétés | Poste | Fin |
|---|---|---|
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Directeur Financier/CFO | 31/05/2010 |
SpePharm Holding BV
 SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries. | Directeur/Membre du Conseil | - |
Formation de Bernd Seibel
| Universität zu Köln | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Finance |
SpePharm Holding BV
SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries. | Health Technology |
Hummingbird Diagnostics GmbH
Hummingbird Diagnostics GmbH Medical SpecialtiesHealth Technology Hummingbird Diagnostics GmbH specializes in patient-friendly diagnostics for early disease detection, personalized medicine, and lifetime health monitoring. Hummingbird Diagnostics is based in Heidelberg, DE and was founded by Jochen Kohlhaas and Karoly Nikolich. The German company uses liquid biopsies based on miRNA biomarkers to detect diseases such as lung cancer, melanoma, breast cancer, multiple sclerosis, Alzheimer's, Parkinson's, heart diseases, and IBD. Jochen Kohlhaas has been the CEO since incorporation. | Health Technology |
Zytoprotec GmbH
Zytoprotec GmbH Pharmaceuticals: MajorHealth Technology Zytoprotec GmbH develops and manufactures drugs for peritoneal dialysis. It specializes in the research and development of its pipeline, which encompasses PD-protec, a patented-protected solution and ICO-protec, a cytoprotective PD solution to address the market for non-glucose based PD solutions. The firm focus areas encompass portfolio management, therapeutic approach, patent management and research services. The company was founded by Karl Altenhuber, Christoph Aufricht and Christian Hoenig in 2007 and is headquartered in Vienna, Austria. | Health Technology |
